Three-Year Medium-Term Management Plan “Transformation” (Revolution into the Future)
First written in FY2020. 7 of 11 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 2 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In fiscal 2023, we launched the 5-year medium-term management plan “Reach Beyond, Together.” Under this plan, we have continued to take on unprecedented challenges to deliver lysosomal disease treatments using our proprietary blood-brain barrier-penetration technology, J-Brain Cargo®, to patients as soon as possible.」
Under the medium-term management plan, the company completed enrollment in the global Phase 3 trial of JR-141, continued clinical development of multiple lysosomal disease candidates, pursued out-licensing of its platform technology, and constructed a new manufacturing facility. - FY2025-H1RestatedAnnual report
「There have been no material changes to the management policy or strategy established by our Group during the interim consolidated accounting period.」
It reconfirmed that there were no significant changes to the management policies or management strategies, including the 3-year medium-term management plan “Transformation.” - FY2024-Q3RestatedAnnual report
「There were no material changes during the nine-month period of the current consolidated fiscal year to the management policies, management strategies or other matters established by the Group.」
It reconfirmed that there were no significant changes to the management policies and management strategies, including the 3-year medium-term management plan “Transformation.” - FY2024-Q2RestatedAnnual report
「There have been no material changes to the management policy or strategy established by our Group during the second quarter of the current consolidated cumulative period.」
It reconfirmed that there were no significant changes to the management policies or management strategies, including the 3-year medium-term management plan “Transformation.” - FY2023-Q2RestatedAnnual report
「There have been no material changes to the management policy or strategy established by our Group during the second quarter of the current consolidated cumulative period.」
It reconfirmed that there were no significant changes to the management policies or management strategies, including the 3-year medium-term management plan “Transformation.” - FY2022AdvancedAnnual report
「In May 2020, we formulated and announced the 3-year medium-term management plan “Transformation” (REVOLUTION into the Future). Under the plan, in preparation for full-scale globalisation, we aim to achieve our medium- to long-term vision “Toward 2030” by transforming not only the quality and scale of our business activities, but also each individual employee who makes up “Team JCR,” the source of our value.」
In the midpoint year of the medium-term management plan “Transformation,” we achieved concrete progress, including the launch of IZCARGO® in Japan, the start of Phase 3 trials in Europe, the United States and Brazil, and the conclusion of a partnership and joint research and development agreement with Takeda Pharmaceutical Company Limited. - FY2022-Q2RestatedAnnual report
「There have been no material changes to the management policy or strategy established by our Group during the second quarter of the current consolidated cumulative period.」
It reconfirmed that there were no significant changes to the management policies or management strategies, including the 3-year medium-term management plan “Transformation.” - FY2021AdvancedAnnual report
「In fiscal 2021, we will launch IZCARGO® in Japan and the Federative Republic of Brazil and advance the global Phase 3 clinical trial, as well as the global Phase 1/2 clinical trial of JR-171, a treatment for Hurler syndrome.」
For the 3-year medium-term management plan “Transformation,” it presented the Japanese approval obtained in the first year as an achievement and outlined the next steps: launches in Japan and Brazil in fiscal 2021, the global Phase 3 trial of JR-141, and the global Phase 1/2 trial of JR-171. - FY2021-Q2RestatedAnnual report
「There have been no material changes to the management policy or strategy established by our Group during the second quarter of the current consolidated cumulative period.」
It reconfirmed that there were no significant changes to the management policies or management strategies, including the 3-year medium-term management plan “Transformation.” - FY2021-Q1RestatedAnnual report
「There were no material changes to the management policy or management strategy established by our Group during the first quarter of the current fiscal year.」
It stated that there were no significant changes to the management policies or management strategies, including the 3-year medium-term management plan “Transformation.” - FY2020First statedAnnual report
「Beginning in fiscal 2020, we announced the 3-year medium-term management plan “Transformation” (Revolution into the Future), leading up to our 50th anniversary in 2025. During the plan period, we will focus on the research and development of a series of lysosomal disease treatments using J-Brain Cargo®, including JR-141 for Hunter syndrome.」
A new 3-year plan, beginning in fiscal 2020 and leading up to the 50th anniversary in 2025, was presented for the first time. Its central initiative is the research and development of lysosomal disease treatments using J-Brain Cargo®.